COMy 2017 | Case study: daratumumab in a relapsed patient
Saad Usmani
• 21 Apr 2017
Saad Usmani, MD, FACP, from the Levine Cancer Institute, Charlotte, NC, discusses an important case study at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. This patient enrolled on daratumumab therapy after his fifth relapse within 18 months of his diagnosis. He had 17p deletion at the time of diagnosis, and had only partial responses to all therapies given. He had a very fast and profound response to daratumumab, leading to MRD negativity. These results show the importance of clinical observations and the immune profiling of these patients.
